NEW YORK (360Dx) – Chembio Diagnostics said today that it plans to submit a pre-market approval application with the US Food and Drug Administration during the first quarter of 2018 to support commercialization of its first point-of-care HIV-syphilis assay in the US. 

The expected submission comes on the back of the firm completing a US clinical trial evaluating the system.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.